Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Rhea-AI Summary

Phio Pharmaceuticals (NASDAQ: PHIO) will present at Renmark's Virtual Non-Deal Roadshow on March 9, 2026 at 10 AM EDT to review its INTASYL siRNA platform and recent clinical progress for lead candidate PH-762.

In a Phase 1b trial, 22 patients completed treatment with no dose-limiting toxicities or serious adverse events; reported pathological response in cSCC was ~65% overall and 85% (6 of 7) in the highest-dose cohort. FDA engagement is targeted for Q2 2026. Cash is projected to sustain operations into H1 2027.

Positive

• Pathological response ~65% in cSCC across all dosing cohorts
• 85% pathological response (6 of 7 patients) in highest-dose cohort
• No dose-limiting toxicities or serious adverse events in 22 patients
• Targeted FDA engagement for next-stage development in Q2 2026
• Cash runway projected into the first half of 2027

Negative

• Small Phase 1b cohort of 22 patients limits statistical certainty
• Early-stage program: PH-762 remains unproven beyond Phase 1b
• Limited cash runway into H1 2027 may require additional financing

Key Figures

Patients treated: 22 patients Dose-escalation cohorts: 5 cohorts cSCC response rate: 65% pathological response +5 more

8 metrics

Patients treated 22 patients PH-762 Phase 1b trial completed treatment

Dose-escalation cohorts 5 cohorts PH-762 Phase 1b intratumoral study

cSCC response rate 65% pathological response cSCC across all PH-762 dosing cohorts

High-dose response rate 85% pathological response Highest-dose PH-762 cohort in cSCC

Responders at high dose 6 of 7 patients Pathological responders in highest-dose cohort

FDA engagement timing Q2 2026 Targeted FDA engagement for next-stage PH-762 development

Cash runway Into first half 2027 Cash and equivalents projected operating runway

Roadshow timing March 9, 2026, 10 AM EDT Renmark virtual non-deal roadshow presentation

Market Reality Check

Price: $1.15 Vol: Volume 855,428 is well be...

low vol

$1.15 Last Close

Volume Volume 855,428 is well below the 20-day average of 10,976,538, suggesting limited participation ahead of this update. low

Technical Shares at $1.15 are trading below the 200-day MA of $1.80, despite a 13.86% gain over the prior session.

Peers on Argus

Argus momentum data flagged a sector move down, with peers like PHGE at -1.59% a...

2 Down

Argus momentum data flagged a sector move down, with peers like PHGE at -1.59% and SNSE at -4.49%. In contrast, PHIO showed a 13.86% gain, indicating stock-specific strength versus generally weaker biotech peers.

Historical Context

5 past events · Latest: Feb 19 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 19	Leadership realignment	Positive	-1.7%	Leadership changes to support PH-762 and PH-894 development.
Feb 10	Safety committee update	Positive	+24.4%	SMC confirms no serious adverse events and strong PH-762 responses.
Jan 26	Investor conference	Neutral	-4.6%	DealFlow conference presentation and PH-762 Phase 1b completion note.
Jan 20	Clinical data update	Positive	-5.3%	Detailed PH-762 Phase 1b efficacy and safety results in skin cancers.
Jan 15	Investor conference	Neutral	+0.9%	Sidoti micro-cap conference with INTASYL and PH-762 update.

Pattern Detected

Positive PH-762 clinical updates have sometimes led to strong gains, while corporate or conference news has produced mixed to slightly negative reactions.

Recent Company History

Over recent months, Phio has focused on advancing PH-762 and its INTASYL platform. On Jan 20, detailed Phase 1b data in cutaneous carcinomas highlighted strong response rates but the stock fell 5.26%. A subsequent Safety Monitoring Committee update on Feb 10 drove a 24.44% gain. Leadership changes on Feb 19 and multiple investor conference appearances saw modest or negative moves. Today’s roadshow event continues the pattern of investor outreach around PH-762 and INTASYL.

Regulatory & Risk Context

Active S-3 Shelf · $24.5 million

Shelf Active

Active S-3 Shelf Registration 2025-11-20

$24.5 million registered capacity

An effective resale registration statement filed on Nov 20, 2025 covers up to 11,763,800 warrant shares for existing holders. Phio is not selling shares under this prospectus and would receive cash only upon warrant exercises, which at full cash exercise would total about $24.5 million. The company has already raised roughly $13.4 million from related warrant exercises, earmarked to support working capital and development of PH-762.

Market Pulse Summary

This announcement highlights continued investor outreach around Phio’s INTASYL platform and lead can...

Analysis

This announcement highlights continued investor outreach around Phio’s INTASYL platform and lead candidate PH-762, reinforcing previously reported Phase 1b data with a 65% overall and 85% high-dose pathological response. The company targets FDA engagement in Q2 2026 and projects cash runway into the first half of 2027. Investors may watch for the formal FDA feedback, design of next-stage trials, and how clinical momentum translates into longer-term development and funding plans.

Key Terms

sirna, intratumoral, cutaneous squamous cell carcinoma, merkel cell carcinoma, +3 more

7 terms

sirna medical

"clinical-stage siRNA biopharmaceutical company developing therapeutics"

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

intratumoral medical

"evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma"

"Intratumoral" describes something that occurs or exists within a tumor, which is an abnormal growth of tissue. For investors, understanding intratumoral is important because it relates to medical treatments or research aimed at targeting the tumor directly, potentially leading to more effective therapies. Think of it as focusing treatment straight into the problem area, much like fixing a leak by working directly on the pipe itself.

cutaneous squamous cell carcinoma medical

"therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel"

A common form of skin cancer that starts in the thin, outer layer of the skin and can grow or, in some cases, spread to nearby tissue or organs. For investors, it matters because diagnosis rates, available treatments, and regulatory approvals shape demand for therapies, influence clinical trial results, and affect potential revenue for companies developing drugs, devices, or diagnostics — like spotting a stubborn weed that may require different tools to remove.

merkel cell carcinoma medical

"melanoma and Merkel cell carcinoma. In its Phase 1b trial"

Merkel cell carcinoma is a rare, fast-growing form of skin cancer that starts in cells near the base of the skin and often spreads quickly to nearby tissues and organs. For investors, it matters because treatments for this aggressive disease can create high-value opportunities or risks: successful drugs or tests can unlock significant revenue and partnerships, while failed trials or regulatory setbacks can sharply affect a biotech company’s prospects — like a single critical test determining whether a new product succeeds or stalls.

pathological response rate medical

"reported a pathological response rate in cSCC across all dosing cohorts"

Pathological response rate is the proportion of treated patients whose tissue samples, examined by a pathologist after therapy, show a meaningful reduction or complete disappearance of disease. For investors, it is an early measurable sign of a treatment’s effectiveness—like checking how many houses are truly fixed after a renovation—and can influence expectations for regulatory approval, future sales, and a company’s valuation.

immuno-oncology medical

"why we believe INTASYL represents a differentiated approach to immuno-oncology"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

non-deal roadshow financial

"live Virtual Non-Deal Roadshow Series hosted by Renmark Financial"

A non-deal roadshow is a planned series of meetings where company executives travel to meet investors and analysts without trying to sell stock or raise money. Think of it like an author’s book tour: the goal is to explain the company’s strategy, answer questions and build relationships so investors better understand the business; that clarity can reduce uncertainty, influence market perception and affect a company’s share price and access to capital in the future.

AI-generated analysis. Not financial advice.

Live Presentation and Q&A: Monday, March 9, 2026 10 AM EDT

CEO to Discuss INTASYL Platform and PH-762 Phase 1b Results

King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will provide an overview of the Company's INTASYL siRNA platform and discuss recent clinical progress and priorities, followed by a live Q&A.

Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately 65%, including an 85% pathological response (6 of 7 patients) in the highest-dose cohort.

Phio has indicated that FDA engagement regarding next-stage clinical development is targeted for the second quarter of 2026 and has reported cash and cash equivalents projected to sustain operations into the first half of 2027.

"We look forward to sharing why we believe INTASYL represents a differentiated approach to immuno-oncology and discussing our strategy for PH-762 as we plan for the next stage of development," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.

Phio's presentation and live Q&A will take place on Monday, March 9, 2026, at 10 AM EDT in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc.

REGISTER HERE: Renmark Virtual Non-Deal Roadshow: NASDAQ - PHIO | Event Registration | Renmark Financial Communications

Please Note: If the link does not work, please copy and paste into your browser. To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.

A replay of the event may be accessed on the Renmark Financial Communications Inc. website at https://www.renmarkfinancial.com/vndrs.

About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL^® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.

For additional information, visit the Company's website, www.phiopharma.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements regarding the anticipated benefits of our INTASYL™ RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs

Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel: (416)-644-2020 or (212)-812-7680
www.renmarkfinancial.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286314

FAQ

What Phase 1b results did PHIO report for PH-762 on March 5, 2026?

Phio reported 22 patients completed Phase 1b with no dose-limiting toxicities or serious adverse events. According to the company, pathological response in cSCC was approximately 65% overall, including 85% in the highest-dose cohort.

When will Phio (PHIO) discuss INTASYL and PH-762 with investors?

Phio will present on March 9, 2026 at 10 AM EDT in Renmark's Virtual Non-Deal Roadshow. According to the company, the presentation includes an overview of INTASYL and a live Q&A with CEO Robert Bitterman.

What does the 85% pathological response in the highest-dose cohort mean for PHIO stock (PHIO)?

The 85% figure refers to 6 of 7 patients showing pathological response in the top dose cohort, indicating promising early signals. According to the company, this is limited by small sample size and requires confirmatory studies.

When is Phio targeting FDA engagement for next-stage development of PH-762 (PHIO)?

Phio is targeting FDA engagement in Q2 2026 to discuss next-stage clinical development. According to the company, this engagement is planned as part of preparing for subsequent trials and regulatory discussions.

How long is Phio's (PHIO) reported cash runway following the March 5, 2026 announcement?

The company reported cash and cash equivalents projected to sustain operations into the first half of 2027. According to the company, this runway frames near-term financing and development planning.

How should investors interpret PH-762 safety data reported by Phio (PHIO)?

The direct takeaway: no dose-limiting toxicities or serious adverse events in 22 treated patients, suggesting a favorable early safety profile. According to the company, larger trials are needed to confirm safety and efficacy.